Please login to the form below

Not currently logged in

Novimmune appoints Guillaume de Sampaïo

He brings experience from Roche, Novartis and Actelion to the Swiss biotech 

Swiss biotech Novimmune has appointed Guillaume de Sampaïo as global head of project management in a role that will also see him sit on its senior management team.

De Sampaïo has 15 years experience in life sciences, having previously served at the likes of Roche, Novartis and Actelion.

Prior to joining Novimmune he served at Danish biotech firm Forward Pharma, where he created and managed its clinical development group.

During that time he contributed to the development of the company's clinical trial portfolio and the facilitation of its successful US IPO during 2014. 

Novimmune chairman and CEO Eduard Holdener said: “With the progression of our R&D pipeline, project management becomes increasingly a crucial element in supporting our growth strategy. 

“Guillaume de Sampaïo will help us to further advance Novimmune as we move closer to the market with our lead program, NI-0501.”

30th November 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Haseeb Ahmad
Can value-based healthcare take off and reach for the skies?
Are companies willing to contribute to the change in the healthcare system?...
Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...